ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1505

Antibodies Binding Ro/SSA and Muscarinic 3 Receptor in Sjogren’s Syndrome

R. Scofield1, Syed Quadri2, Valerie Harris2, Biji Kurien2 and Kristi Keolsch2, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University of Oklahoma Health Sciences Center, Oklahoma City, OK

Meeting: ACR Convergence 2020

Keywords: Autoantibody(ies), Sjögren's Syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: Sjögren’s Syndrome (1502–1506)

Session Type: Abstract Session

Session Time: 5:00PM-5:50PM

Background/Purpose: Sjögren’s syndrome is characterized by exocrine gland dysfunction and autoantibody production.  Some data suggest autoantibodies binding the muscarinic 3 receptor (M3R) mediate poor function of the salvary gland.  We have previously produced recombinant human monoclonal antibodies (rhMab) from antibody-secreting B cells (ASC) infiltrating the salivary glands of Sjögren’s syndrome subjects.  We undertook this study to determine anti-M3R properties of these rhMab.

Methods: Minor salivary gland biopsies were obtained in a comprehensive sicca evaluation clinic.   ABCs were single cell purified with heavy and light genes amplified by PCR.  These genes were then expressed in 239 cells with production of monoclonal IgG or IgM.  The rhMab were assayed for anti-Ro, Ro peptide and M3R extracellular loop (ECL) peptides by ELISA.  Ability to act as an agonist or antagonist of M3R was assessed via GeneBlazer™ M3-NFAT-bla CHO-K1 (M3R) cell line (K1716). 

Results: We studied 47 rhMabs from SS subjects and 18 from non-SS sicca subjects.  There were 10/47 and 0/18 hrMab from the SS and non-SS sicca subjects, respectively, that were positive for binding to M3R ECL2 (p=0.05) and 5/47 SS vs. 0/18 non-SS sicca subjects that were positive for M3R ECL3 (p=0.311). Four of the rhMabs (1-G04k, 1-E06k, 2-D06k and 5-E04k) from one SS patient (pSS-3) bound both M3R ECL2 and ECL3.  When we considered positivity to either M3R ECL2 or ECL3, 11 of 47 rhMabs from SS subjects bound, while 0 of 18 rhMabs from non-SS sicca subjects bound (p=0.03 by 2-tailed Fisher’s Exact Test).  Several rhMab that bound M3R ECL2 showed high affinity binding (Kd values ranging from 10-7 to 10-9).  Among the Ro60-binding rhMab derived from SS subjects, 8/23 (34.8%) also bound M3R ECL2.  and 4/23 (17%) bound the M3R ECL3 by ELISA. None of the anti-Ro60 rhMab from the non-SS sicca subjects bound either M3R ECL2 or ECL3.  Of 65 rhMab, 4 from the SS group (all from pSS-3) and 2 from the non-SS sicca group (1 from NSS-1 and 1 from NSS-4) showed M3R antagonist activity.

Conclusion: Recombinant monoclonal antibodies derived from salivary gland infiltrating antibody secreting cells bind M3R extracellular loop.  Some of these antibodies show M3R inhibitory activity; and, thus, may be directly involved in salivary gland dysfunction.


Disclosure: R. Scofield, None; S. Quadri, None; V. Harris, None; B. Kurien, None; K. Keolsch, None.

To cite this abstract in AMA style:

Scofield R, Quadri S, Harris V, Kurien B, Keolsch K. Antibodies Binding Ro/SSA and Muscarinic 3 Receptor in Sjogren’s Syndrome [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/antibodies-binding-ro-ssa-and-muscarinic-3-receptor-in-sjogrens-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/antibodies-binding-ro-ssa-and-muscarinic-3-receptor-in-sjogrens-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology